Warner Pharmaceuticals announced that the company will increase the investment amount for the construction project of a green intelligent manufacturing base with an annual output of 3,000 tons of high-end APIs and intermediates carried out by Zhigen Pharmaceutical, a wholly-owned company, from no more than 650 million yuan to no more than 800 million yuan. The funding source is its own and self-raised funds. The matter has been reviewed and approved by the sixth meeting of the fourth board of directors of the company. There is no need to submit it to the shareholders' meeting for consideration, it does not involve related transactions, and it does not constitute a major asset restructuring. At present, the civil engineering of the project has been basically completed, and some workshops have entered the trial production stage. There is a risk that operation and profitability will fall short of expectations in the future.

Warner Pharmaceuticals announced that the company will increase the investment amount for the construction project of a green intelligent manufacturing base with an annual output of 3,000 tons of high-end APIs and intermediates carried out by Zhigen Pharmaceutical, a wholly-owned company, from no more than 650 million yuan to no more than 800 million yuan. The funding source is its own and self-raised funds. The matter has been reviewed and approved by the sixth meeting of the fourth board of directors of the company. There is no need to submit it to the shareholders' meeting for consideration, it does not involve related transactions, and it does not constitute a major asset restructuring. At present, the civil engineering of the project has been basically completed, and some workshops have entered the trial production stage. There is a risk that operation and profitability will fall short of expectations in the future.